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Abstract: Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium 
(K+) channel-blocking compounded dalfampridine, also known as fampridine, and chemically 
4-aminopyridine or 4-AP, which received regulatory approval in the United States for the treatment of 
walking in patients with multiple sclerosis (MS) in January 2010. Two pivotal Phase 3 clinical trials 
demonstrated significant improvements in walking in patients with the four primary forms of MS 
following administration of dalfampridine ER tablets 10 mg twice daily. The drug is thought to act 
by restoring conduction in focally demyelinated axons and by enhancing neurotransmission, thereby 
leading to improved neurological function. This review describes how dalfampridine represents a 
new pharmacotherapeutic approach to the clinical management of mobility impairment. It describes 
the mechanism of action and chemistry of dalfampridine ER, its pharmacokinetics, tolerability, and 
side effects, and the outcomes of multicenter trials showing its efficacy in improving walking speed. 
Clinician and patient global assessments, as well as patient self-assessment of the impact of MS on 
their gait   disability, confirm clinically relevant benefit from the therapy. Patients tolerate the drug well 
and their improvement in terms of household and community ambulation, inferred from analysis of 
pooled data from several studies, is likely to translate into benefits in the performance of   instrumental 
activities of daily living and a reduction in the neuropsychiatric burden of disease.
Keywords: dalfampridine ER, Ampyra®, fampridine-SR, 4-aminopyridine, multiple sclerosis, 
demyelination
Walking impairment in multiple sclerosis
Impaired ability to walk constitutes one of the major disabling neuromuscular deficits 
associated with multiple sclerosis (MS).1–3 It is often the most visible sign of MS and 
has been reported to affect 80% of persons within 15 years of disease onset.1,4,5 At this 
time there is a 40% probability of need for walking assistance and a 25% probability 
of need for a wheelchair. As a consequence of compromised activities of daily living 
that involve walking about the home or in the community, impairments of gait lead to 
loss of independence, decreased sense of self-worth due the external appearance of 
disablement, lost employment opportunities and reduced quality of life.3,6 The impact 
of mobility impairment on patient autonomy, caregiver burden, mood, and the costs 
of care are disproportionately high relative to those associated with other neurologic 
diseases2 and compound the already heavy neuropsychiatric burden of the disease.2,7–9 
As such, maintaining mobility is ranked as one of the highest priorities among patients 
with MS, regardless of disease duration or level of disability.3
Conventional approaches to the management of gait impairment primarily involve 
physical rehabilitation and the functional retraining of gait. This may be coupled with Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  pharmacological management of symptoms that compromise 
gait, such as spasticity. Gait retraining is usually done by 
physical therapists and often involves the use of assistive 
mobility aids such as orthoses, canes, crutches, or walking 
frames. In advanced stages of the disease power scooters or 
wheelchairs may be prescribed.10 A recent survey identified 
the fact that many patients elect not to use these devices; 37% 
of respondents did not use aids out of embarrassment and a 
further 36% reported that they did not use their prescribed 
aids as much as they should.11 Mobility aids do provide 
  supports that constrain the disablement, but do not restore 
neuromuscular function per se. Similarly, pharmacologic 
agents for the management of spasticity reduce abnormali-
ties of tone that impair locomotor capacity, but do so without 
reversing the underlying gait deficit. Antispastic and spas-
molytic agents may also lead to unwanted central depressant 
actions of anergia and increased fatigue, thereby further 
contributing to the loss of mobility. Pharmacotherapeutics 
designed to slow progression of the disease, eg, interferons 
and glatiramer acetate, also provide little or no direct symp-
tomatic relief of gait disorders, and recovery of function 
occurs only if the disease goes into remission.
Against the backdrop of this conventional management 
of impaired gait in MS, there has been considerable interest 
in the development of a new class of   pharmacotherapeutics 
designed to reverse the underlying neurologic deficits asso-
ciated with demyelination of axons within the CNS and 
thereby restore neurological function. The first drug in this 
class to be approved by the US Food and Drug Administra-
tion (FDA) is dalfampridine extended release (ER) (Acorda 
Therapeutics, Inc., New York), marketed under the name 
Ampyra®. In a series of Phase 2 and Phase 3 randomized 
clinical trials, dalfampridine ER 10 mg tablets taken twice 
daily improved patients’ speed on the Timed 25-Foot Walk 
test (T25FW).12–14 Based on the magnitude of the improve-
ments in gait, and by reference to studies in other populations, 
the expected clinical benefits would be notable improvements 
in the patients’ functional capacity to ambulate within their 
home or in the community.15 Several previous reviews of 
this drug have elaborated on the underlying pharmacology, 
the developmental history of the drug, and the outcome of 
clinical trials up to the time of regulatory approval by the 
FDA in January 2010.16–21
The US FDA determined that the previously adopted 
nonproprietary name “fampridine” was too similar to another 
approved medication and could lead to medical errors. The US 
Adopted Name Council therefore changed the   nonproprietary 
name to “dalfampridine”. In addition, the FDA determined 
that the term “extended release” will be used to refer to 
this formulation rather than the previously used “sustained 
release”. These conventions have been employed in this 
manuscript. The drug is referred to by its International Non-
proprietary Name of “fampridine” outside the US.
The present review briefly summarizes the   pharmacological 
mechanism of action and pharmacokinetics of dalfampridine 
ER in individuals with MS. It also describes the quantitative 
and subjectively reported outcomes of clinical trials demon-
strating efficacy for walking, safety, and tolerability. Unique 
to this review is commentary on the clinical significance of 
the observed therapeutic efficacy, and the current status of 
regulatory approval in other parts of the world. The review 
concludes with some perspective on how future research 
with dalfampridine might be directed to further explore the 
impact of the drug on neuropsychiatric burden in a more 
direct, rather than inferential, manner.
The information used to inform this review was 
largely derived from PubMed searches using the MeSH 
terms “4-aminopyridine”, “fampridine”, “dalfampridine”, 
“ampyra”, “human”, “clinical trials”, “multiple sclerosis”, 
and identifying publications in English from 1985 to 2011. 
The search was completed March 15, 2011 and a total of 
101 published articles were retrieved. Primary consider-
ation was given to the original reports of Phase 2 and 3 
clinical trials with supplemental information derived from 
subsequent reviews,   meta-analyses, editorials, conference 
  proceedings and abstracts. No attempt was made herein 
to independently conduct a formal systematic review of 
the quality of evidence emerging from these publications; 
however precis of both the critical analyses and the rebuttals 
are described in order to retain impartiality of this review. 
  Information on mechanism of action and pharmacological 
properties was derived from studies involving animal models 
of   demyelination. The FDA website (www.  accessdata.fda.gov) 
provided access to prescribing information,   tolerability, and 
adverse effects of   dalfampridine ER. The Biogen Idec website 
(www.  biogenidec.com) provided information on the regula-
tory status of the drug in Europe. Biogen Idec has the license 
to market dalfampridine ER outside the United States.
MS, demyelination, and the 
mechanism of action  
of dalfampridine
MS is primarily an inflammatory disorder of the central 
  nervous system (CNS) in which focal lymphocytic infiltra-
tion leads to damage of myelin and axons.22 Demyelination of 
axons within the CNS is the most diagnostic neuropathology Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
231
Dalfampridine eR effect on walking in MS patients
of MS in the early stages of the disease, and this has prompted 
characterization of MS as the archetypical demyelinating 
disease. Myelin deficits may show up as vacuolation, degen-
eration of the inner lamellae, focal thinning, disseminated foci 
of demyelination, or incomplete remyelination. These myelin 
deficits are thought to arise initially from T cell, macrophage, 
and antibody-mediated oligodendrogliopathy and later from 
ischemic or toxic virus, or metabolic processes.23,24 As the 
disease progresses, there is commensurately more evidence of 
axonal pathology, with a distribution that varies with clinical 
  phenotype. Axonal pathology accounts for the nonreversible 
nature of the neurological deficits and some of the neuropsy-
chiatric symptoms in the progressive forms of disease.25–29
Myelin deficits lead to exposure of paranodal, fast, 
  voltage-gated potassium (K+) channels, and the attendant 
abnormal K+ conductance impairs action potential electrogen-
esis, repetitive axonal discharge, and propagation.30–32 Axonal 
conduction deficits that arise from demyelination underlie the 
initial clinical presentation of each of the four primary clas-
sifications of MS: relapsing-remitting, primary-progressive, 
secondary-progressive, and progressive-relapsing. Prominent 
among the neurologic deficits are visual disturbances, fatigue, 
and motor and sensory deficits including weakness, incoor-
dination, and spasticity, all of which contribute to impaired 
balance and mobility, and compound independently impaired 
emotional and cognitive states.
Dalfampridine is a broad spectrum potassium (K+) chan-
nel blocking agent, with the capacity to improve conduction 
across demyelinated internodes in axons of the central ner-
vous system. It has dose-dependent specificity for different 
types of K+ channels.33 Dalfampridine prolongs the duration 
of the Na++ action current at the internode; this increases the 
safety factor for conduction (ie, the ratio of action current 
generated by an impulse to the minimum amount of action 
current needed to maintain conduction) and thus can reverse 
conduction block due to focal demyelination. This mode of 
action has been established in various ex vivo and in vivo 
axonal preparations and animal models of demyelination.34–38 
K+ channel blocking compounds also enhance neuroneuronal 
and neuromuscular transmission by increasing presynaptic 
and end-terminal calcium (Ca++) influx.39,40 Collectively 
these properties are thought to underlie the restored axonal 
conduction and neurological function reported in patients 
with MS and other demyelinating disorders.
Chemistry of dalfampridine
Dalfampridine is also known by its chemical name, 
  4-aminopyridine, and is a member of a family of   mono-amino 
and di-amino derivatives of pyridine, with a molecular 
structure of C5H6N2. The pyridine ring has an amino substi-
tution in the 4 position as shown in Figure 1. The molecular 
weight of dalfampridine is 94.12.41 An important feature of 
dalfampridine ER that distinguishes it from the compounded, 
immediate-release formulations of 4-aminopyridine is its 
prolonged pharmacokinetic half-life. The extended-release 
technology, developed by Élan Pharma International Ltd. 
(EPIL) and termed MXDASTM, consists of a proprietary 
polymer matrix that controls release by diffusion resulting in 
lower peak serum levels and longer duration of action.42
Pharmacokinetics of dalfampridine 
ER in patients with MS
The extended-release form of dalfampridine was developed 
commercially to overcome some of the pharmacokinetic and 
safety concerns associated with immediate-release formulations 
of the drug which had become available from compounding 
pharmacies.43,44 Concerns also existed about sustained-release 
forms of the drug available from compounding pharmacies, 
as they lacked quality control over manufacturing and distri-
bution processes. Most notably, toxicity was associated with 
the high peak plasma concentrations of the immediate-release 
formulation45 and the potency of the sustained-release forms 
was inconsistent, leading to risks associated with irregular 
dosing. Commercial development of the extended-release 
tablet form, with lower peak plasma concentrations, was 
designed to mitigate these risks and to ensure quality control 
and bring good manufacturing practices to the formulation 
and distribution of the drug. Reducing dosing requirements of 
dalfampridine ER to twice daily, instead of 3 to 5 times per day 
for   immediate-release formulations, would also be expected to 
enhance patient   compliance with oral medication.
N
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The basic pharmacokinetics of an extended release 
  formulation of dalfampridine in MS were initially reported by 
Bever et al.46 Twelve patients with Extended Disability Status 
Scale (EDSS) scores of 4 to 7.5 participated in an open-label 
study in which they received escalating doses (7.5 mg to 25 mg 
every 12 hours) of dalfampridine. The mean time-to-peak and 
serum half-life were 5.0 and 5.2 hours, respectively, and maxi-
mum tolerable doses varied from 10 mg twice daily to 25 mg 
twice daily. These parameters were subsequently confirmed 
and elaborated by Vollmer and Henney47 in a multicenter, open-
label, evaluation of dose-proportionality in 24 patients with 
clinically definite MS. The pharmacokinetics of single escalat-
ing doses of dalfampridine ER (5–20 mg) are summarized in 
Table 1. In a second study, the steady state pharmacokinetic 
properties of dalfampridine ER 20 mg twice daily were evalu-
ated in the same patients over a 14-day period and compared 
with their single-dose study results.48 The pharmacokinetic 
parameters on day 1 replicated those of the single-dose study. 
The time to maximum plasma concentration (Tmax) values 
did not differ between days 1, 8, and 15 in the steady-state 
study, and the values found in the single-dose study (range 
3.25–3.78 hours). The maximum plasma concentration (Cmax) 
values on day 8 and 15 were significantly higher than those on 
day 1, and in the single-dose study reflected the accumulation 
of dalfampridine with multiple dosing. With the exception 
of one case of severe nausea, all adverse events in this study 
were mild to moderate and there were no significant changes 
in clinical laboratory values, vital signs, physical examination, 
or cardiac function (QTc intervals). This study provided sup-
port for the use of twice-daily dosing, approximately 12 hours 
apart, in this population. The absence of harmful effects on 
cardiac function has been confirmed elsewhere.49
In other studies, dalfampridine ER has been shown to 
be completely absorbed from the gastrointestinal gut fol-
lowing oral administration and to be almost completely 
(95.9%) eliminated unchanged via the kidneys (0.5% 
recovered from feces).50 Small percentages are eliminated 
as the metabolite 3-hydroxy-4-aminopyridine (4.3%) and 
3-hydroxy-4-aminopyridine sulfate (2.6%), neither of which 
is   pharmacologically active at K+ channels.50,51   Dalfampridine 
ER has a relative bioavailability of 96% compared with 
an aqueous oral solution. Plasma protein binding is low 
(1%–3%) and the drug has an apparent volume of distribu-
tion of 2.6 L/kg. There are no indications of abnormal liver 
enzymes associated with the use of dalfampridine ER and 
the drug does not adversely interact with baclofen (10 mg) 
or interferon-β-1b (subcutaneous injections of 8 million 
units), two medications commonly prescribed for use by MS 
patients.51 Dalfampridine ER kinetics were not affected by 
coadministration of these drugs.51
With respect to the interaction of dalfampridine ER with 
other drugs, it is noted in the prescribing information51 that 
in vitro data with human liver microsomes showed that dal-
fampridine ER was not a direct or time-dependent inhibitor of 
CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, or CYP3A4/5. Dalfampridine ER is not likely to 
affect the pharmacokinetics of drugs that are substrates of 
these enzymes. Other in vitro studies with cultured human 
hepatocytes with 0.025 µM, 0.25 µM, 2.5 µM, and 25 µM 
dalfampridine ER had little or no effect on CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5 enzyme 
activities. Consequently, the potential for dalfampridine ER 
to induce human hepatocytes at therapeutic concentrations 
is remote. In vitro, dalfampridine ER is not a substrate or an 
inhibitor for the p-glycoprotein transporter. The pharmacoki-
netics of dalfampridine ER are unlikely to be affected by drugs 
that inhibit the p-glycoprotein transporter, and dalfampridine 
ER is not likely to affect the pharmacokinetics of drugs that 
are substrates of the p-glycoprotein transporter.
In patients with renal impairment, accumulation of drug 
may occur with repeated administration. The drug should be 
used cautiously in individuals with mild renal impairment 
(creatinine clearance [CrCl] 51–80 mL/min) as the risk of 
seizures in these patients is unknown and the drug is not 
appropriate for patients with moderate or severely impaired 
renal function (CrCl # 50 mL/min). Plasma   levels of 
Table 1 Dalfampridine pharmacokinetic parameters
Value by dalfampridine dose, mean (SE)
Pharmacokinetic  
parameter
5 mg  10 mg 15 mg 20 mg
Tmax, h 3.88 (0.20) 3.92 (0.25) 3.36 (0.25) 3.57 (0.25)
Cmax, ng/mL 13.13 (0.64) 25.23 (1.39) 37.00 (1.99) 49.23 (3.16)
AUC, ng ⋅ h/mL 122.1 (9.4) 252.2 (15.6) 394.4 (22.2) 511.3 (27.7)
AUC 0→∞, ng ⋅ h/mL 146.4 (10.0) 283.2 (18.0) 428.9 (25.6) 546.7 (31.4)
Copyright© 2009. elsevier. Adapted with permission from vollmer T, Henney HR. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release 
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  dalfampridine ER in these patients may approach those seen 
at a dose of 15 mg twice daily, a dose that may be associated 
with an increased risk of seizures.52 Because patients with 
renal impairment would require a dose lower than 10 mg 
twice daily and no strength smaller than 10 mg is available, 
dalfampridine ER is contraindicated in patients with mod-
erate to severe renal impairment. Elderly patients are more 
likely to have decreased renal function and it is particularly 
important to know the estimated CrCl in these patients 
before initiating treatment with dalfampridine ER. Estimated 
CrCl should be known before initiating any treatment with 
dalfampridine ER.
The risks of dalfampridine ER and pregnancy are classi-
fied as Pregnancy Category C.51 There are no adequate and 
well-controlled studies of dalfampridine ER in pregnant 
women. Administration of dalfampridine ER to animals 
during pregnancy and lactation resulted in decreased off-
spring viability and growth at doses similar to the maximum 
recommended human dose of 20 mg/day. Dalfampridine ER 
should be used during pregnancy only if the potential benefit 
justifies the potential risk to the fetus.51
Tolerability and adverse events  
(side effects)
The treatment-emergent adverse events associated with the 
use of dalfampridine ER are summarized in Table 2. The table 
reports pooled data from one Phase 2 and two Phase 3 studies 
and includes placebo data for comparison.51 Generally the 
drug is well tolerated by the majority of individuals within 
the recommended dosing of 10 mg twice daily; most adverse 
events are mild and resolve without management within hours 
or a few days. Mild dizziness, gastrointestinal discomfort, and 
some agitation or wakefulness are frequently   encountered. 
At higher doses, eg, at 20 to 30 mg twice daily, the risk 
of more serious and intolerable adverse events increases. 
The most serious risk is for the induction of epileptiform 
seizures, eg, focal, tonic-clonic, and complex partial, and 
individuals who have a history or indicated risk of seizures 
should not expose themselves to further risk. In one of the 
Phase 2 trials,13 2 out of a total of 159 patients experienced 
seizures while taking 20 mg twice daily; 1 of these patients 
had accidentally overdosed on 2 occasions, and experienced 
2 partial complex seizures. There are no reports of recurrent 
seizures being induced by dalfampridine-ER. In the most 
recent Phase 3 clinical trial of dalfampridine ER (n = 239), 
4 patients in the placebo group and 4 patients in the dalfam-
pridine ER group withdrew because of adverse events.14 
The largest proportional differences between treatment and 
placebo groups were found in adverse events of insomnia, 
headache, dizziness, nausea, back pain, and balance disorder, 
as reported using MedDRA terms (Medical Dictionary for 
Regulatory Activities). The majority of treatment-related 
events were mild or moderate in intensity, transient, and did 
not lead to discontinuation from the study.
Patient education about the dangers of using   immediate- 
or extended-release forms of dalfampridine, in a nonregu-
lated or uncontrolled manner, or with accidental overdose, 
is clearly warranted as serious adverse events have been 
documented.43,45,53,54 The same applies to the risk of self-
dosing dalfampridine ER above the prescribed limits 
  particularly in the circumstance when some evidence of 
efficacy is present within the prescribed dose and individu-
als seek to gain greater benefit. Attention to the prescribing 
information for dalfampridine ER, medication labeling, 
and directions for use is essential.51 The multilevel Risk 
Evaluation and Mitigation Strategy (REMS) that Acorda 
Therapeutics, Inc. has implemented, involving medication 
guide and communication plan, is described on the FDA 
website.55
Randomized clinical trials showing 
efficacy in improving walking ability
A series of uncontrolled Phase 1 and controlled Phase 2 
clinical trials of dalfampridine and dalfampridine ER, con-
ducted over a 20-year span, established some indications of 
efficacy for a variety of neurological impairments associated 
with MS and generally supported the safety and tolerability 
of the drug.12,56–63
In 2008, Goodman et al12 reported a Phase 2   parallel-group 
dose-comparison trial in which subjects were randomly 
assigned to receive dalfampridine-ER 10 mg twice daily 
(n = 52), 15 mg (n = 50), 20 mg (n = 57) or placebo   
(n = 47). A 2-week dose-escalation period was followed by 
a 12-week stable-dose phase and a 1-week dose-reduction 
phase. The percentage change in the T25FW test was the 
primary outcome. The average increase in walking speed 
was 23.5% (10 mg), 26.0% (15 mg), 15.8% (20 mg), and 
12.8% (placebo). The dalfampridine ER treatments did not 
yield significant improvement over placebo. A subsequent 
“responder” analysis revealed that the percentage of sub-
jects exhibiting an a priori specified improvement of .20% 
were higher in the dalfampridine ER-treated groups (35.3% 
[10 mg], 36.0% [15 mg], and 38.6% [20 mg], respectively) 
compared with the 8.5% responding to placebo. As with 
the primary outcome these results did not attain statistical 
significance, and there was no indication of a dose-response, Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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but they did engender some optimism that the drug may be 
helpful to a subset of individuals with mobility impairment. 
The only endpoint attaining significance was the change 
from baseline in lower extremity strength, which showed 
an improvement of roughly 15% over placebo in both the 
10- and 15-mg dose groups.
The responder type analyses prompted Kryscio64 to observe 
that the investigators had discovered an “innovative method for 
identifying consistent responders to the drug, providing clini-
cians with a promising tool for treating a subset of MS patients”. 
Kryscio64 also questioned whether this was a true positive 
finding or an example of data massaging. While acknowledg-
ing that responder analyses are acceptable within the context 
of regulatory approval by the FDA, Kryscio64 also noted that 
the failure to detect statistically significant outcomes may have 
been due to a lack of statistical power. A major disadvantage 
of the responder analysis approach is reduced power relative 
to that based on group averages.65 In this particular study, to 
make the responder analysis the primary endpoint and meet 
FDA requirements on comparing multiple doses with placebo, 
the investigators would have needed to accrue 195 patients per 
group to show a doubling of responders with equivalent power 
(80% power with an adjusted type I error rate of 0.016).
Two pivotal Phase 3 trials were then designed to rigor-
ously evaluate the efficacy of dalfampridine ER in enhanc-
ing performance on the T25FW in patients with clinically 
definite MS. The responder analysis was selected as the 
analytic method to be employed. In order to directly assess the 
clinical relevance of the outcomes, the 12-Item MS Walking 
Scale (MSWS-12) was also administered.66 This scale has 
been shown to be a reliable and valid patient-based measure 
of the impact of MS on walking and has been shown to be 
more responsive than other walking-based scales.66 These 
trials were conducted under the auspices of FDA Special 
Protocol Assessments.
The first Phase 3 trial (MS-F203)13 was a double-blind, 
placebo-controlled, parallel-group study conducted in 
33 centers in the United States and Canada. Participants 
received dalfampridine ER 10 mg twice daily or placebo, 
over a 14-week treatment period, with each arm of the study 
preceded by a 2-week placebo run-in. All participants were 
followed for 4 weeks after completion of the double-blind 
phase of the trial. A total of 301 patients was randomized 
into the study, on a 3:1 ratio, to receive treatment drug or 
placebo, and of these 283 completed all study visits. The 
primary outcome measure, the T25FW, was evaluated 4 times 
prior to treatment, 4 times during treatment, and twice in the 
follow-up period. Patients were allowed to use an assistive 
device while walking, as long as the same device was used 
consistently across visits. The a priori defined responder 
analysis was then employed to determine the number of 
patients who showed a consistent improvement in walking 
speed during the double-blind treatment period. The primary 
efficacy endpoint was calculated using a modified intention-
to-treat analysis. Secondary outcomes of efficacy related to 
neuromuscular benefits included measures of lower extrem-
ity muscle strength (Lower Extremity Manual Muscle Test 
or LEMMT) and spasticity (Ashworth Score). The Subject 
Global Impression (SGI), Clinician Global Impression (CGI), 
and MSWS-12 were also used as secondary outcomes to 
validate the clinical meaningfulness of the response criterion 
of consistent improvement on the T25FW.
The primary result of MS-F203 was that the proportion 
of timed walk responders in the dalfampridine ER-treated 
group (34.8%) was significantly greater than in the group 
given placebo (8.3%). Responders to treatment had an aver-
age increase in walking speed of 25.2% during the course 
of treatment whereas the placebo group showed a 4.7% 
improvement. The increase in walking speed was maintained 
throughout the double-blind treatment period. The responders 
reported greater improvement in the self-assessment of walk-
ing capacity (MSWS-12) than nonresponders. A significant 
increase in leg strength was observed in dalfampridine ER 
responders compared with subjects in the placebo group. 
The responder group also showed greater improvement 
in MSWS-12 scores than nonresponders. These results 
Table  2  Adverse  reactions  occurring  in  $2%  of  patients 
treated with dalfampridine eR tablets and more frequently than 
placebo-treated patients in clinical trials
Placebo  
(N = 238)
Ampyra  
10 mg every 12 h   
(N = 400)
Urinary tract infection 8 12
insomnia 4 9
Dizziness 4 7
Headache 4 7
Nausea 3 7
Asthenia 4 7
Back pain 2 5
Balance disorder 1 5
Multiple sclerosis relapse 3 4
Paresthesia 3 4
Nasopharyngitis 2 4
Constipation 2 3
Dyspepsia 1 2
Pharyngolaryngeal pain 1 2
Notes: Numbers represent percentage of subjects experiencing the adverse reaction.
Adapted from United States Food and Drug Administration: Prescribing information 
for AmpyraTM  (dalfampridine)  extended  release  tablets.  www.accessdata.fda.gov/
drugsatfda_docs/label/.../022250s000 lbl.pdf. Accessed March 24, 2011.51Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  supported the a priori FDA-approved efficacy criterion that 
treatment with   dalfampridine ER 10 mg twice daily would 
significantly increase the chance of having a positive response 
of improved walking speed that is consistent over time and 
perceived subjectively as a meaningful improvement in 
ambulatory deficits.
The second Phase 3 trial (MS-F204) was also a double-
blind, placebo-controlled, parallel group study in patients 
with clinically definite MS. This was conducted across 
39 centers in the United States and Canada and involved 
239 patients who were randomized to treatment with 
dalfampridine ER 10 mg twice daily or placebo on a 1:1 
ratio. For inclusion, participants had to have a T25FW time 
between 8 and 45 seconds, and the T25FW was again used 
as the primary outcome measure. The treatment duration 
was shortened to 9 weeks because of the previously dem-
onstrated stability of beneficial changes in walking speed 
over a 3-month period.
The results of this trial established that the proportion 
of T25FW responders was higher in the dalfampridine ER 
group (42.9%) compared with the placebo group (9.3%) 
and the average improvement in walking speed for respond-
ers was 24.7% or 0.51 ft/s. The increase in walking speed 
among dalfampridine ER-treated responders was maintained 
across the double-blind treatment period and was reversed 
with treatment discontinuation. The average changes from 
baseline in MSWS-12 score during the double-blind treat-
ment period were -6.04 for responders compared with 0.85 
for nonresponders, indicating a significant reduction in self-
assessed ambulatory disability among responders. SGI, and 
CGI scores both confirmed significant benefit for responders. 
This study thus provided class 1 evidence that dalfampridine 
ER produced clinically meaningful improvement in walking 
ability in a subset of people with MS.
Subsequent to completion of these two Phase 3 studies, 
pooled analyses have been undertaken combining the results 
of one of the Phase 2 trials, with comparable design, and 
the two Phase 3 trials. The conclusions drawn were that the 
efficacy of dalfampridine ER, as defined by the timed-walk 
responder rate, was independent of demographics, disease 
characteristics, and use of immunomodulatory drugs.67 
Moreover, the benefits of dalfampridine ER were seen 
across a wide range of baseline deficits in walking ability.15 
Using a scale derived from the post-stroke population, which 
characterized functional walking into household ambulation 
(,1.3 ft/s), limited community ambulation (1.3– 2.6 ft/sec), 
or full community ambulation (.2.6 ft/s), Edwards et al15 
reported that a substantial proportion of responders in the 
three studies sufficiently improved their walking speed to 
represent a change from less to more function within a class 
and in many cases individuals would be expected to move 
from one ambulation class to another.
The role of dalfampridine therapy 
for gait disorders in MS
The primary indication for dalfampridine ER is for walking 
in MS patients regardless of the severity of deficit and disease 
characteristics. Pharmacotherapy would be done in conjunc-
tion with the use of mobility aids and would be complemen-
tary to symptomatic management strategies such as the use of 
antispastic agents. The use of dalfampridine ER concurrently 
with baclofen has been shown to be safe in the course of the 
clinical studies, which did not exclude concurrent treatment; 
indeed the reported antispastic properties of dalfampridine 
ER reported in some of the Phase 2 and 3 trials, and evidenced 
by improved scores on the Ashworth scale, may indicate the 
possibility of reducing the dosing requirements of anti-spastic 
medications that are being used, though this has not been 
established by clinical studies. The demonstrated efficacy 
and safety of dalfampridine ER in trials in which concurrent 
use of immunomodulatory, disease-modifying agents were 
allowed suggests that parallel pharmacotherapeutic strategies 
may be employed.
The reported clinical benefits of dalfampridine ER extend 
beyond those for which class 1 evidence exists. There is 
persuasive experimental evidence of improvements in leg 
strength and reductions in spasticity, both of which may 
enable greater independence with respect to transfers and 
activities of daily living. Indeed, Kachuck18 has reported on 
a number of benefits revealed on clinical examination and 
by clinical experience but not necessarily amenable to, or 
captured in, formal clinical trial protocols. These include 
improvements in endurance or fatigability, visual acuity, 
bladder/bowel/sexual dysfunction. Improvements in mental 
sharpness, problem solving and reading comprehension 
have also been reported anecdotally. Some experimental 
support for these findings has been noted.56–62 Clearly, clini-
cal judgement will prevail as to how such benefits to these 
symptoms, if observed, influence concurrent management 
approaches.
Challenges to the purported clinical 
benefit of dalfampridine
There have been two recently documented challenges to 
the acceptance of dalfampridine ER as a therapeutic agent 
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published in Annals of Neurology in 2010, by Hauser and 
Johnston,68 the authors maintained that the drug “improved 
the 25 foot walk time by an average of less than one   second; 
0.88 seconds to be exact in the first trial and 0.5 seconds 
in the second. Although statistically significant, the ben-
efit appears modest for a treatment that costs $13,000 
  annually”. The authors also noted the continued risk of 
seizures and implied there was little gain from this medi-
cation over the immediate-release formulations available 
through compounding pharmacies at one-fiftieth of the 
cost. A rebuttal by Cohen and Blight,69 on behalf of Acorda 
Therapeutics, and published in January 2011, focused 
on some inaccuracies in the editorial concerning the 
development of the drug, highlighted the risks of serious 
dosing errors associated with compounded formulations 
of 4-AP,43,44 and addressed what they considered to be an 
inaccurate reflection of the average change in walking times 
experienced by the patients. They noted that the results 
reported in the editorial “appear to have been derived by an 
unusually complex, post hoc manipulation of a subset of the 
trial data”. The a priori specified analysis of the study data 
focused on reproducible improvements in walking speed, 
acknowledging the day-to-variability in functional capacity 
experienced by individuals with MS. They noted that in 
the 37.6% of responders to dalfampridine ER there was an 
average 25% improvement in walking speed compared to 
6.5% in placebo-treated patients and 7.0% in dalfampridine 
ER-treated nonresponders. The clinical meaningfulness of 
this improvement in the responder group was reflected by 
a significant reduction in self-assessed walking disability, 
evident in the MSWS-12.
In the second challenge, which occurred about the same 
time as the rebuttal by Cohen and Blight, the Committee for 
Medicinal Products for Human Use (CHMP), the European 
agency responsible for conducting the initial assessment of 
medicines for which an EU-wide marketing authorization is 
sought, rejected the application for dalfampridine ER (sub-
mitted by Biogen Idec under the name Fampyra™).70 CHMP 
was also not convinced that Fampyra’s effect on the walking 
speed was a meaningful benefit for patients. Moreover, they 
argued that the effect on walking speed could not be linked 
to meaningful improvements such as better coordination, 
balance, or stamina or increased range of motion. The 
Committee was not persuaded that the medicine’s benefits 
outweighed its side effects. The Committee also noted the 
lack of adequate long-term data on the medicine’s benefits 
and safety as well as data on some groups of patients, such 
as the elderly and patients with epilepsy or heart problems. 
Biogen Idec is appealing this decision at the time of this 
review going to press.
Impact of dalfampridine ER  
on the neuropsychiatric burden  
of diseases in MS
The neuropsychiatric burden of MS is multifaceted and 
complex.7–9 It includes neuropathology-related impairments 
of emotional control and cognitive processes brought about 
by demyelination and/or axonal pathology in various loca-
tions within the brain sub-serving these functions. Benedict 
et al,28 for example, have reported that measures of tissue 
atrophy including whole-brain and central atrophy are 
especially well correlated with and predictive of cognitive 
impairment. The burden also involves disability-related, 
“reactive” processes such as mood disorders associated 
with diagnosis, experienced disability and its social 
consequences, and concern for the future because of the 
progressive nature of the disease and the interaction with 
the normal functional decline of aging; ie, “accelerated 
degradation”.2,71 Compounding the burden on the patient 
is the huge impact of their needs on caregivers,72 both 
contracted caregivers and loved ones, and the economics 
of managing their disability, often when their employment 
has been compromised.2
How does dalfampridine ER impact these states? There 
is no empirical evidence from controlled trials to directly 
address these issues. Inference drawn from the Phase 3 tri-
als and earlier studies does suggest that improved mobility 
may mitigate the dependence on others for some activities 
of daily living, including personal care and homemaking 
tasks, and may enable greater community involvement or 
extended employment. Such benefits would be expected to 
translate to fewer feelings of dependence and burden of the 
stigma associated with disability. The extent to which this 
becomes clinically and personally meaningful will likely 
depend on the specific disease state and circumstances of 
each patient.
The neurobiological mechanism of action of dalfampri-
dine ER in restoring conduction in demyelinated axons is 
unlikely to be confined to the sensory and motor pathways 
involved in gait, even if there exist subtle differences in K+ 
channel typology and distribution in different parts of the 
CNS.33 Indeed one could reasonably project that dissemi-
nated foci of demyelination throughout the CNS all represent 
viable targets for the drug action. In this case, one might 
expect to find that dalfampridine ER is capable of reversing 
demyelination-based cognitive and emotional deficits and Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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thereby attenuating the neuropsychiatric burden directly. 
Smits et al,73 in a small (n = 20) randomized, double-blind, 
crossover trial, examined the effects of 2 weeks treatment 
with immediate-release oral 4-aminopyridine (dalfampridine) 
on cognitive function in patients with definite MS. Although 
there was a trend for improved performance with the study 
medication for two of the neuropsychological tests (10/36 
delayed recall and the Paced Auditory Serial Addition Test of 
attention), the study failed to demonstrate significant group 
effects of dalfampridine on cognitive function. The extent 
to which medication-induced improvements in performance 
will be feasible and able to yield clinical benefit, however, 
must be weighed in the context of the evolving awareness 
of distinct patterns and regional distribution of gray matter 
damage that are associated with cognitive impairment in MS 
patients.27 The correspondence between lesion formation 
and gray matter atrophy distribution varies in the different 
forms of MS. Thus the degree to which dalfampridine may 
be useful will depend on the degree to which demyelination, 
as distinct from axonal pathology, contributes to the cognitive 
dysfunction and this may vary among individuals and among 
clinical phenotypes.
Implications for further research
Two obvious lines of enquiry emerge from the above 
discussion of the impact of dalfampridine ER on walking 
ability and the corollary of attenuating the neuropsychiatric 
burden. The first is to more directly examine the impact of 
drug-  induced improvements in walking on instrumental 
activities of daily living, employment, or other rehabilitation 
outcomes. Although challenging because of the multivariate 
nature of factors influencing performance and outcome, it is 
through empirically demonstrating benefit in these areas that 
some of the reactive burden may be lifted.   Accompanying 
those forms of benefit would likely be demonstrable 
enhancements in the quality of life.74 The second line of 
enquiry would be to directly evaluate the efficacy of the 
drug in influencing biomarkers or other indices of cognitive 
or neuropsychiatric impairment. These types of studies may 
provide focus for further Phase 2 or 3 studies, or postmarket-
ing Phase 4   investigations that will enable new indications 
to be identified.
As a first-generation pharmaceutical designed to reverse 
demyelination-induced conduction deficits, dalfampridine ER 
is likely to spawn further developments with novel K+ channel 
blocking agents with similar or more refined mechanisms of 
action. New insights are emerging about the large family of 
voltage-gated K+ ion channels.75 Elaboration of the   properties 
of these channels and their relationship to disease and neu-
rological dysfunction is helping to define new therapeutic 
targets.76
Summary
Dalfampridine ER is the first of a new class of pharma-
cotherapeutics designed to restore neurological function 
  compromised by central demyelination. It has received 
approval from the FDA in the United States for the improve-
ment of walking in people with MS and is currently pend-
ing regulatory approval in Canada. The FDA has required 
additional studies investigating the efficacy of lower doses 
of dalfampridine ER, notably 5 mg tablets. In Europe the 
drug (under the name Fampyra) has been denied approval 
for marketing by the CHMP because of what was considered 
small benefit relative to risk, a decision currently under appeal 
by Biogen Idec. The improvements in gait brought about by 
the drug are evident as increased walking speed on a timed 
walking test (T25FW), positive global assessments by clini-
cian and patient, and reduced walking disability as reflected 
in the patient self-assessed MSWS-12. Since mobility impair-
ments contribute greatly to the patient burden of disease 
with respect to activities of daily living, employment, self-
image, and mood, improvements in gait would be projected 
to mitigate some of the reactive neuropsychiatric burden of 
disease. Whether or not there are direct effects of the drug in 
reversing demyelination-induced axonal conduction deficits 
underlying emotional and cognitive impairment remains to 
be determined by further research.
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consulting with Acorda Therapeutics, Inc., New York, the 
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